%	O
%	O
TITLE	O

Molecular	O
profiling	O
of	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
.	O

%	O
%	O
ABSTRACT	O

Head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
(	O
HNSCC	O
)	O
exhibits	O
high	O
rates	O
of	O
recurrence	O
,	O
and	O
with	O
few	O
approved	O
targeted	O
agents	O
,	O
novel	O
treatments	O
are	O
needed	O
.	O

We	O
analyzed	O
a	O
molecular	O
profiling	O
database	O
for	O
the	O
distribution	O
of	O
biomarkers	O
predictive	O
of	O
chemotherapies	O
and	O
targeted	O
agents	O
.	O
Seven	B-Study_Cohort
hundred	I-Study_Cohort
thirty	I-Study_Cohort
-	I-Study_Cohort
five	I-Study_Cohort
patients	I-Study_Cohort
with	I-Study_Cohort
advanced	I-Study_Cohort
HNSCC	I-Study_Cohort
(	O
88	O
with	O
known	O
human	O
papillomavirus	O
[	O
HPV	O
]	O
status	O
)	O
,	O
were	O
profiled	O
using	O
multiple	O
platforms	O
(	O
gene	O
sequencing	O
,	O
gene	O
copy	O
number	O
,	O
and	O
protein	O
expression	O
)	O
.	O
Among	O
the	O
entire	O
patient	O
population	O
studied	O
,	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
was	O
the	O
protein	O
most	O
often	O
overexpressed	O
(	O
90	O
%	O
)	O
,	O
TP53	O
gene	O
most	O
often	O
mutated	O
(	O
41	O
%	O
)	O
,	O
and	O

phosphatidylinositol	O
3	O
-	O
kinase	O
(	O
PIK3CA	O
)	O
most	O
often	O
amplified	O
(	O
40	O
%	O
;	O
nâ€‰=â€‰5	O
)	O
.	O

With	O
the	O
exception	O
of	O
TP53	O
mutation	O
,	O
other	O
biomarker	O
frequencies	O
were	O
not	O
significantly	O
different	O
among	O
HPV	O
-	O
positive	O
or	O
HPV	O
-	O
negative	O
patients	O
.	O

PIK3CA	O
mutations	O
and	O
phosphatase	O
and	O
tensin	O
homolog	O
(	O
PTEN	O
)	O
loss	O
are	O
frequent	O
events	O
,	O
independent	O
of	O
HPV	O
status	O
.	O

The	O
immune	O
response	O
-	O
modulating	O
programmed	O
cell	O
death	O
1	O
(	O
PD1	O
)	O
and	O
programmed	O
cell	O
death	O
ligand	O
1	O
(	O
PDL1	O
)	O
axis	O
was	O
active	O
across	O
sites	O
,	O
stages	O
,	O
and	O
HPV	O
status	O
.	O
Molecular	O
profiling	O
utilizing	O
multiple	O
platforms	O
provides	O
a	O
range	O
of	O
therapy	O
options	O
beyond	O
standard	O
of	O
care	O
.	O

Â©	O
2015	O
Wiley	O
Periodicals	O
,	O
Inc	O
.	O

Head	O
Neck	O
38	O
:	O
E1625	O
-	O
E1638	O
,	O
2016	O
.	O

%	O
%	O
MATERIALS	O
AND	O
METHODS	O

Patients	O
and	O
multiplatform	O
molecular	O
profiling	O

Molecular	O
markers	O
that	O
have	O
been	O
associated	O
with	O
sen	O
-	O
sitivity	O
or	O
resistance	O
to	O
cytotoxic	O
and	O
targeted	O
agents	O
(	O
theranostic	O
biomarkers	O
)	O
were	O
assayed	O
by	O
immunohisto	B-HPV_Lab_Technique
-	I-HPV_Lab_Technique
chemistry	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
in	B-HPV_Lab_Technique
situ	I-HPV_Lab_Technique
hybridization	I-HPV_Lab_Technique
,	O
and	O
gene	O
sequencing	O
.	O

The	O
biomarker	O
to	O
drug	O
associations	O
are	O
derived	O
from	O
pro	O
-	O
spective	O
or	O
retrospective	O
clinical	O
research	O
studies	O
in	O
vari	O
-	O
ous	O
solid	O
tumors	O
,	O
including	O
HNSCC	O
,	O
or	O
are	O
part	O
of	O
the	O
National	O
Comprehensive	O
Cancer	O
Network	O
(	O
NCCN	O
)	O
Bio	O
-	O
markers	O
Compendium	O
.	O
15	O
For	O
some	O
biomarkers	O
,	O
therapeu	O
-	O
tic	O
associations	O
are	O
suggested	O
based	O
on	O
emerging	O
data	O
(	O
eg	O
,	O
investigational	O
agents	O
in	O
clinical	O
trials	O
)	O
.	O

This	O
study	O
includes	O
data	O
from	O
patients	O
with	O
refractory	O
,	O
aggressive	O
,	O
and	O
/	O
or	O
metastatic	O
head	O
and	O
neck	O
cancer	O
,	O
pro	O
-	O
spectively	O
assayed	O
by	O
at	O
least	O
1	O
platform	O
(	O
immunohisto	B-HPV_Lab_Technique
-	I-HPV_Lab_Technique
chemical	I-HPV_Lab_Technique
[	I-HPV_Lab_Technique
IHC	I-HPV_Lab_Technique
]	I-HPV_Lab_Technique
,	O
in	B-HPV_Lab_Technique
situ	I-HPV_Lab_Technique
hybridization	I-HPV_Lab_Technique
[	I-HPV_Lab_Technique
ISH	I-HPV_Lab_Technique
]	I-HPV_Lab_Technique
,	O
and	O
Sanger	O
/	O
next	O
-	O
generation	O
sequencing	O
[	O
NGS	O
]	O
)	O
by	O
Caris	O
Life	O
Sciences	O
(	O
July	O
30	O
,	O
2009	O
to	O
February	O
24	O
,	O
2015	O
)	O
,	O
and	O
includes	O
a	O
sub	O
-	O
group	O
of	O
patients	O
with	O
known	O
HPV	O
status	O
(	O
n	O
5	O
88	O
)	O
.	O

Formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
(	O
FFPE	O
)	O
HNSCC	O
sam	B-HPV_Sample_Type
-	I-HPV_Sample_Type
ples	I-HPV_Sample_Type
were	O
sent	O
by	O
treating	O
physicians	O
for	O
analysis	O
of	O
thera	O
-	O
nostic	O
biomarkers	O
.	O

All	O
tumor	O
samples	B-HPV_Sample_Type
were	O
verified	O
by	O
board	O
-	O
certified	O
pathologists	O
for	O
sufficient	O
tumor	O
content	O
,	O
specimen	B-HPV_Sample_Type
quality	O
,	O
and	O
confirmation	O
of	O
diagnosis	O
.	O

The	O
test	O
-	O
ing	O
performed	O
for	O
each	O
patient	O
may	O
vary	O
based	O
on	O
the	O
physician’s	O
request	O
,	O
tissue	B-HPV_Sample_Type
availability	O
,	O
technology	O
advance	O
-	O
ments	O
(	O
eg	O
,	O
Sanger	O
vs	O
.	O

NGS	O
)	O
,	O
and	O
emerging	O
clinical	O
eviden	O
-	O
tiary	O
support	O
for	O
theranostic	O
biomarkers	O
.	O

Immunohistochemistry	O

IHC	B-HPV_Lab_Technique
analysis	I-HPV_Lab_Technique
of	I-HPV_Lab_Technique
24	I-HPV_Lab_Technique
proteins	I-HPV_Lab_Technique
was	I-HPV_Lab_Technique
performed	I-HPV_Lab_Technique
on	I-HPV_Lab_Technique
FFPE	I-HPV_Lab_Technique
tumor	I-HPV_Lab_Technique
samples	I-HPV_Lab_Technique
using	I-HPV_Lab_Technique
commercially	I-HPV_Lab_Technique
available	I-HPV_Lab_Technique
detection	I-HPV_Lab_Technique
kits	I-HPV_Lab_Technique
and	I-HPV_Lab_Technique
automated	I-HPV_Lab_Technique
staining	I-HPV_Lab_Technique
techniques	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
Benchmark	I-HPV_Lab_Technique
XT	I-HPV_Lab_Technique
;	I-HPV_Lab_Technique
Ventana	I-HPV_Lab_Technique
Medical	I-HPV_Lab_Technique
Systems	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
Tucson	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
AZ	I-HPV_Lab_Technique
;	I-HPV_Lab_Technique
and	I-HPV_Lab_Technique
Autostainer	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
LInk	I-HPV_Lab_Technique
48	I-HPV_Lab_Technique
;	I-HPV_Lab_Technique
Dako	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
Carpinteria	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
CA	I-HPV_Lab_Technique
)	O
.	O

Antibody	O
clones	O
and	O
thresholds	O
used	O
are	O
provided	O
in	O
Supplementary	O
Table	O
S1	O
,	O
online	O
only	O
.	O

Appropriate	O
positive	O
and	O
negative	O
controls	O
were	O
used	O
for	O
all	O
proteins	O
tested	O
.	O

IHCs	B-HPV_Lab_Technique
were	O
scored	O
man	O
-	O
ually	O
by	O
board	O
-	O
certified	O
pathologists	O
using	O
predefined	O
thresholds	O
consisting	O
of	O
intensity	O
of	O
staining	O
(	O
0	O
,	O
11	O
,	O
21	O
,	O
and	O
31	O
)	O
and	O
percentage	O
of	O
tumor	O
cells	O
that	O
stained	O
posi	O
-	O
tive	O
.	O

Thresholds	O
are	O
derived	O
from	O
peer	O
-	O
reviewed	O
clinical	O
literature	O
,	O
which	O
associates	O
response	O
to	O
treatment	O
to	O
bio	O
-	O
marker	O
status	O
.	O

Tests	O
are	O
interpreted	O
as	O
positive	O
or	O
nega	O
-	O
tive	O
,	O
and	O
the	O
expression	O
data	O
are	O
represented	O
as	O
a	O
distribution	O
(	O
percentage	O
)	O
of	O
positive	O
or	O
negative	O
results	O
observed	O
in	O
the	O
cohort	O
tested	O
.	O

In	B-HPV_Lab_Technique
situ	I-HPV_Lab_Technique
hybridization	I-HPV_Lab_Technique

Gene	O
copy	O
number	O
alterations	O
of	O
cMET	O
,	O
EGFR	O
,	O
HER2	O
,	O
PIK3CA	O
,	O
and	O
TOP2A	O
were	O
analyzed	O
by	O
DNA	B-HPV_Lab_Technique
ISH	I-HPV_Lab_Technique
using	I-HPV_Lab_Technique
fluorescence	I-HPV_Lab_Technique
in	I-HPV_Lab_Technique
situ	I-HPV_Lab_Technique
hybridization	I-HPV_Lab_Technique
and	I-HPV_Lab_Technique
/	I-HPV_Lab_Technique
or	I-HPV_Lab_Technique
chromogenic	I-HPV_Lab_Technique
in	I-HPV_Lab_Technique
situ	I-HPV_Lab_Technique
hybridization	I-HPV_Lab_Technique
probes	I-HPV_Lab_Technique
as	I-HPV_Lab_Technique
part	I-HPV_Lab_Technique
of	I-HPV_Lab_Technique
the	I-HPV_Lab_Technique
automated	I-HPV_Lab_Technique
staining	I-HPV_Lab_Technique
techniques	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
Benchmark	I-HPV_Lab_Technique
XT	I-HPV_Lab_Technique
;	I-HPV_Lab_Technique
Ventana	I-HPV_Lab_Technique
Medical	I-HPV_Lab_Technique
Systems	I-HPV_Lab_Technique
)	O
and	O
automated	O
imaging	O
systems	O
(	O
BioView	O
,	O
Billerica	O
,	O
MA	O
)	O
.	O

Cutoffs	O
are	O
provided	O
in	O
the	O
Supplementary	O
Table	O
S1	O
,	O
online	O
only	O
.	O

The	O
ratio	O
of	O
gene	O
to	O
pericentromeric	O
regions	O
of	O
chromosome	O
7	O
(	O
EGFR	O
,	O
cMET	O
)	O
,	O
17	O
(	O
HER2	O
,	O
TOP2A	O
)	O
,	O
and	O
3	O
(	O
PIK3CA	O
)	O
were	O
used	O
to	O
determine	O
increases	O
in	O
gene	O
copy	O
number	O
.	O

Ratios	O
higher	O
than	O
defined	O
cutoff	O
were	O
con	O
-	O
sidered	O
positive	O
and	O
ratios	O
less	O
than	O
defined	O
cutoff	O
were	O
considered	O
negative	O
.	O

HPV	O
DNA	O
status	O
was	O
determined	O
by	O
ISH	B-HPV_Lab_Technique
using	I-HPV_Lab_Technique
the	I-HPV_Lab_Technique
INFORM	I-HPV_Lab_Technique
HPV	I-HPV_Lab_Technique
III	I-HPV_Lab_Technique
Family	I-HPV_Lab_Technique
16	I-HPV_Lab_Technique
probe	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
Ven	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
tana	I-HPV_Lab_Technique
Medical	I-HPV_Lab_Technique
Systems	I-HPV_Lab_Technique
)	O
,	O
which	O
detects	O
high	O
-	O
risk	O
HPV	O
sub	O
-	O
types	O
(	O
16	O
,	O
18	O
,	O
31	O
,	O
33	O
,	O
39	O
,	O
45	O
,	O
51	O
,	O
52	O
,	O
56	O
,	O
58	O
,	O
and	O
66	O
)	O
.	O

Observation	O
of	O
single	O
or	O
multiple	O
punctate	O
hybridization	O
signals	O
localized	O
to	O
tumor	O
cell	O
nuclei	O
was	O
scored	O
as	O
posi	O
-	O
tive	O
,	O
and	O
the	O
lack	O
of	O
any	O
hybridization	O
signals	O
was	O
consid	O
-	O
ered	O
negative	O
.	O

Sanger	O
sequencing	O

Sanger	O
sequencing	O
included	O
selected	O
regions	O
of	O
BRAF	O
,	O
cKIT	O
,	O
EGFR	O
,	O
KRAS	O
,	O
NRAS	O
,	O
and	O
PIK3CA	O
and	O
was	O
per	O
-	O
formed	O
using	O
M13	B-HPV_Lab_Technique
-	I-HPV_Lab_Technique
linked	I-HPV_Lab_Technique
polymerase	I-HPV_Lab_Technique
chain	I-HPV_Lab_Technique
reaction	I-HPV_Lab_Technique
pri	O
-	O
mers	O
designed	O
to	O
flank	O
and	O
amplify	O
targeted	O
sequences	O
.	O

Polymerase	B-HPV_Lab_Technique
chain	I-HPV_Lab_Technique
reaction	I-HPV_Lab_Technique
products	O
were	O
bidirectionally	O
sequenced	O
using	O
the	O
BigDye	O
Terminator	O
version	O
1	O
.	O
1	O
chemistry	O
,	O
and	O
analyzed	O
using	O
the	O
3730	O
DNA	O
Analyzer	O
(	O
Applied	O
Biosystems	O
,	O
Grand	O
Island	O
,	O
NY	O
)	O
.	O

Sequence	O
traces	O
were	O
analyzed	O
using	O
Mutation	O
Surveyor	O
software	O
version	O

3	O
.	O
25	O
(	O
Soft	O
Genetics	O
,	O
State	O
College	O
,	O
PA	O
)	O
.	O

Next	O
-	O
generation	O
sequencing	O

NGS	O
was	O
performed	O
on	O
genomic	O
DNA	O
isolated	O
from	O
FFPE	O
tumor	O
tissue	B-HPV_Sample_Type
using	O
the	O
Illumina	O
MiSeq	O
platform	O
.	O

Specific	O
regions	O
of	O
47	O
genes	O
were	O
amplified	O
using	O
the	O
Illumina	O
TruSeq	O
Amplicon	O
Cancer	O
Hotspot	O
panel	O
.	O
16	O
All	O
variants	O
reported	O
are	O
detected	O
with	O
>	O
99	O
%	O
confidence	O

(	O
based	O
on	O
mutation	O
frequency	O
and	O
amplicon	O
coverage	O
)	O

with	O
an	O
average	O
sequencing	O
depth	O
of	O
>	O
1000	O
X	O
.	O

TABLE	O
1	O
.	O

Clinicopathological	O
characteristics	O
of	O
735	O
patients	O
with	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
molecularly	O
profiled	O
.	O

Abbreviations	O
:	O
HNSCC	O
,	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
;	O
HPV	O
,	O
human	O
papillomavirus	O
;	O
NOS	O
,	O
not	O
otherwise	O
specified	O
.	O

*	O
Including	O
:	O
connective	O
and	O
soft	O
tissue	B-HPV_Sample_Type
of	O
head	O
,	O
face	O
,	O
and	O
neck	O
(	O
n	O
5	O
138	O
)	O
;	O
lymph	O
nodes	O
(	O
n	O
5	O
93	O
)	O
;	O
lung	O
and	O
bronchus	O
(	O
n	O
5	O
75	O
)	O
;	O
liver	O
(	O
n	O
5	O
34	O
)	O
;	O
bones	O
and	O
joints	O
(	O
n	O
5	O
26	O
)	O
;	O
pleura	O
(	O
n	O
5	O
7	O
)	O
;	O
chest	O
and	O
NOS	O
(	O
n	O
5	O
6	O
)	O
;	O
skin	O
(	O
n	O
5	O
3	O
)	O
;	O
colon	O
(	O
n	O
5	O
5	O
)	O
;	O
mediastinum	O
(	O
n	O
5	O
4	O
)	O
;	O
pelvis	O
and	O
NOS	O
(	O
n	O
5	O
3	O
)	O
;	O
retroperitoneum	O
and	O
peritoneum	O
(	O
n	O
5	O
5	O
)	O
;	O
stomach	O
(	O
n	O
5	O
3	O
)	O
;	O
vertebra	O
(	O
n	O
5	O
5	O
)	O
;	O
adrenal	O
gland	O
(	O
n	O
5	O
3	O
)	O
;	O
brain	O

(	O
n	O
5	O
2	O
)	O
;	O
orbit	O
(	O
n	O
5	O
1	O
)	O
;	O
and	O
small	O
bowel	O
(	O
n	O
5	O
1	O
)	O
.	O

Statistical	O
methods	O

Retrospective	O
analysis	O
of	O
biomarker	O
frequency	O
distribu	O
-	O
tions	O
was	O
attained	O
using	O
standard	O
descriptive	O
statistics	O
.	O

The	O
2	O
-	O
tailed	O
Fisher’s	O
exact	O
test	O
was	O
performed	O
using	O
JMP	O
version	O
10	O
.	O
0	O
(	O
SAS	O
Institute	O
,	O
Cary	O
,	O
NC	O
)	O
to	O
test	O
where	O
fre	O
-	O
quencies	O
differed	O
by	O
subgroup	O
.	O

A	O
2	O
-	O
tailed	O
p	O
value	O
.	O
05	O
was	O
considered	O
statistically	O
significant	O
and	O
Bonferroni	O
correction	O
was	O
used	O
to	O
correct	O
for	O
multiple	O
comparisons	O
.	O

Validation	O
and	O
institutional	O
review	O
board	O

All	O
methods	O
utilized	O
in	O
this	O
study	O
were	O
clinically	O
vali	O
-	O
dated	O
to	O
at	O
least	O
Clinical	O
Laboratory	O
Improvement	O
Amendments	O
,	O
College	O
of	O
American	O
Pathologists	O
,	O
and	O
International	O
Organization	O
for	O
Standardization	O
(	O
ISO	O
)	O
15189	O
.	O

This	O
retrospective	O
analysis	O
utilized	O
previously	O
col	O
-	O
lected	O
deidentified	O
data	O
created	O
under	O
the	O
Caris	O
honest	O
-	O
broker	O
policy	O
and	O
followed	O
consultation	O
with	O
the	O
Western	O
Institutional	O
Review	O
Board	O
(	O
IRB	O
)	O
,	O
which	O
is	O
the	O
IRB	O
of	O
record	O
for	O
Caris	O
Life	O
Sciences	O
.	O

The	O
project	O
was	O
deemed	O
exempt	O
from	O
IRB	O
oversight	O
and	O
consent	O
requirements	O
were	O
waived	O
.	O

